Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial
- PMID: 20952003
- DOI: 10.1016/j.juro.2010.08.028
Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial
Abstract
Purpose: The short-term outcomes of initial detrusor injections vs combined detrusor-trigone botulinum toxin-A injections were determined in patients with spinal cord injury-neurogenic detrusor overactivity.
Materials and methods: Adults with refractory spinal cord injury-neurogenic detrusor overactivity who strictly discontinued anticholinergics were recruited for the study. At a 1:1 ratio patients randomly received 300 U botulinum toxin-A intradetrusor injections excluding the trigone (detrusor arm) or 200 U intradetrusor plus 100 U intratrigonal injections (combined arm). Study end points were determination of the impact on incontinence episodes, complete dryness, quality of life, reusing anticholinergics, maximum detrusor pressure, reflex volume, maximum cystometric capacity, vesicoureteral reflux and adverse events. Patients were evaluated at baseline, and 2, 8, 12 and 18 weeks after injection. Statistical significance was considered at p<0.05.
Results: Analysis included 18 patients per arm with no significant baseline differences. On within group analysis all parameters improved significantly compared to baseline. On between group analysis in the detrusor vs the combined arm at week 8 incontinence decreased by 52.4% vs 80.9% (number needed to treat 1.91 vs 1.23 patients, p<0.001), complete dryness was achieved in 33.3% vs 66.7% of patients (number needed to treat 3 vs 1.5, p<0.001) and quality of life score was decreased by 46.76% vs 48.13% (number needed to treat 2.14 vs 2.08, p<0.44). The absolute difference was 60% vs 82.5% for reflex volume (p<0.001), 66.2% vs 68.4% for maximum cystometric capacity (p<0.22) and -42.3% vs -41.9% for maximum detrusor pressure (p<0.21). At week 18 anticholinergics were needed again in 9 (50%) and 4 patients (22.2%) patients, respectively. No patient showed new or upgraded vesicoureteral reflux or reported significant adverse events.
Conclusions: In the short term all parameters improved significantly in each arm. The superiority of including rather than excluding the trigone was significant.
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Incontinence: Trigonal injection of botulinum toxin-A improves outcome.Nat Rev Urol. 2010 Dec;7(12):648. doi: 10.1038/nrurol.2010.197. Nat Rev Urol. 2010. PMID: 21188778 No abstract available.
Similar articles
-
Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.J Urol. 2011 Jun;185(6):2229-35. doi: 10.1016/j.juro.2011.02.004. Epub 2011 Apr 16. J Urol. 2011. PMID: 21497851 Clinical Trial.
-
Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.Urology. 2011 Feb;77(2):439-45. doi: 10.1016/j.urology.2010.06.003. Epub 2010 Aug 30. Urology. 2011. PMID: 20800886 Clinical Trial.
-
Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.J Urol. 2011 Apr;185(4):1344-9. doi: 10.1016/j.juro.2010.12.002. Epub 2011 Feb 22. J Urol. 2011. PMID: 21334639 Clinical Trial.
-
Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.Arch Phys Med Rehabil. 2013 Aug;94(8):1473-81. doi: 10.1016/j.apmr.2013.04.011. Epub 2013 Apr 28. Arch Phys Med Rehabil. 2013. PMID: 23632286 Review.
-
Botulinum toxin treatment for bladder dysfunction.Int J Urol. 2013 Oct;20(10):956-62. doi: 10.1111/iju.12188. Epub 2013 May 2. Int J Urol. 2013. PMID: 23634720 Review.
Cited by
-
Botulinum toxin for conditions of the female pelvis.Int Urogynecol J. 2013 Jul;24(7):1073-81. doi: 10.1007/s00192-012-2035-1. Epub 2013 Jan 24. Int Urogynecol J. 2013. PMID: 23344218 Review.
-
The Action of Botulinum Toxin A on the Sternocleidomastoid Muscle: An Experimental Study on Rats.ScientificWorldJournal. 2022 Feb 8;2022:2188783. doi: 10.1155/2022/2188783. eCollection 2022. ScientificWorldJournal. 2022. PMID: 35177957 Free PMC article.
-
Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis.Front Neurol. 2021 Oct 8;12:651635. doi: 10.3389/fneur.2021.651635. eCollection 2021. Front Neurol. 2021. PMID: 34690904 Free PMC article.
-
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.Drugs. 2025 May;85(5):677-693. doi: 10.1007/s40265-025-02171-3. Epub 2025 Apr 1. Drugs. 2025. PMID: 40167970
-
Updates in the management of the overactive bladder in patients with myelomeningocele.Curr Urol Rep. 2011 Dec;12(6):413-8. doi: 10.1007/s11934-011-0218-9. Curr Urol Rep. 2011. PMID: 22037959 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical